allogeneic tumor cell vaccine (PT 107) / Technomark Life Sci, Pique Therapeutics, Inc. - LARVOL DELTA

Daily Adaptive RadioTherapy in Postoperative HypofrActionated Salvage radiothERapy for Prostate Cancer Patients (DART-PHASER): Early Clinical and Dosimetric Results (ASTRO 2025) - P=N/A | "We found a significant improvement for pelvis PTV95% (<0.0001), pelvis PTV107% (<0.0001), and bowel Dmax (<0.0001) in the adapted plan, compared to the scheduled plan... Preliminary data seems to show minimal acute toxicity. CT-based adaptive moderate hypofractionated radiotherapy might be beneficial in the PC postoperative setting. A longer follow up is needed to confirm these data and evaluate late toxicity."

Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Comparison of VMAT (volumetric modulated arc therapy) delivery of high-dose palliative radiotherapy (RT) to lung via Eclipse Planning System (EPS), to conventional palliative radiotherapy delivery via ADW planning system (BTOG 2023) - "VMAT planning for appropriate palliative patients can achieve comparable PTV coverage, better dose distribution and improved OAR constraints: all factors relevant in a patient group where overall survival at 1 year was 40%."

Gastrointestinal Disorder • Lung Cancer • Oncology • Pneumonia • Solid Tumor